Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rachael Z. Stolzenberg-Solomon is active.

Publication


Featured researches published by Rachael Z. Stolzenberg-Solomon.


Nature Genetics | 2009

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Laufey Amundadottir; Peter Kraft; Rachael Z. Stolzenberg-Solomon; Charles S. Fuchs; Gloria M. Petersen; Alan A. Arslan; H. Bas Bueno-de-Mesquita; Myron D. Gross; Kathy J. Helzlsouer; Eric J. Jacobs; Andrea Z. LaCroix; Wei Zheng; Demetrius Albanes; William R. Bamlet; Christine D. Berg; Franco Berrino; Sheila Bingham; Julie E. Buring; Paige M. Bracci; Federico Canzian; Françoise Clavel-Chapelon; Sandra Clipp; Michelle Cotterchio; Mariza de Andrade; Eric J. Duell; John W. Fox; Steven Gallinger; J. Michael Gaziano; Edward Giovannucci; Michael Goggins

We conducted a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide. We genotyped 558,542 SNPs in 1,896 individuals with pancreatic cancer and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study. We conducted a combined analysis of these groups plus an additional 2,457 affected individuals and 2,654 controls from eight case-control studies, adjusting for study, sex, ancestry and five principal components. We identified an association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 (combined P = 5.37 × 10−8; multiplicative per-allele odds ratio 1.20; 95% confidence interval 1.12–1.28). This SNP maps to the first intron of the ABO blood group gene. Our results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreatic cancer than those with groups A or B.


WOS | 2013

Genome-wide association study of circulating vitamin D levels

Jiyoung Ahn; Kai Yu; Rachael Z. Stolzenberg-Solomon; K. Claire Simon; Marjorie L. McCullough; Lisa Gallicchio; Eric J. Jacobs; Alberto Ascherio; Kathy J. Helzlsouer; Kevin B. Jacobs; Qizhai Li; Stephanie J. Weinstein; Mark P. Purdue; Jarmo Virtamo; Ronald L. Horst; William Wheeler; Stephen J. Chanock; David J. Hunter; Richard B. Hayes; Peter Kraft; Demetrius Albanes

The primary circulating form of vitamin D, 25-hydroxy-vitamin D [25(OH)D], is associated with multiple medical outcomes, including rickets, osteoporosis, multiple sclerosis and cancer. In a genome-wide association study (GWAS) of 4501 persons of European ancestry drawn from five cohorts, we identified single-nucleotide polymorphisms (SNPs) in the gene encoding group-specific component (vitamin D binding) protein, GC, on chromosome 4q12-13 that were associated with 25(OH)D concentrations: rs2282679 (P = 2.0 × 10−30), in linkage disequilibrium (LD) with rs7041, a non-synonymous SNP (D432E; P = 4.1 × 10−22) and rs1155563 (P = 3.8 × 10−25). Suggestive signals for association with 25(OH)D were also observed for SNPs in or near three other genes involved in vitamin D synthesis or activation: rs3829251 on chromosome 11q13.4 in NADSYN1 [encoding nicotinamide adenine dinucleotide (NAD) synthetase; P = 8.8 × 10−7], which was in high LD with rs1790349, located in DHCR7, the gene encoding 7-dehydrocholesterol reductase that synthesizes cholesterol from 7-dehydrocholesterol; rs6599638 in the region harboring the open-reading frame 88 (C10orf88) on chromosome 10q26.13 in the vicinity of ACADSB (acyl-Coenzyme A dehydrogenase), involved in cholesterol and vitamin D synthesis (P = 3.3 × 10−7); and rs2060793 on chromosome 11p15.2 in CYP2R1 (cytochrome P450, family 2, subfamily R, polypeptide 1, encoding a key C-25 hydroxylase that converts vitamin D3 to an active vitamin D receptor ligand; P = 1.4 × 10−5). We genotyped SNPs in these four regions in 2221 additional samples and confirmed strong genome-wide significant associations with 25(OH)D through meta-analysis with the GWAS data for GC (P = 1.8 × 10−49), NADSYN1/DHCR7 (P = 3.4 × 10−9) and CYP2R1 (P = 2.9 × 10−17), but not C10orf88 (P = 2.4 × 10−5).


JAMA Internal Medicine | 2010

Anthropometric Measures, Body Mass Index and Pancreatic Cancer: a Pooled Analysis from the Pancreatic Cancer Cohort Consortium (PanScan)

Alan A. Arslan; Kathy J. Helzlsouer; Charles Kooperberg; Xiao-Ou Shu; Emily Steplowski; H. Bas Bueno-de-Mesquita; Charles S. Fuchs; Myron D. Gross; Eric J. Jacobs; Andrea Z. LaCroix; Gloria M. Petersen; Rachael Z. Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Laufey Amundadottir; William R. Bamlet; Aurelio Barricarte; Sheila Bingham; Heiner Boeing; Marie-Christine Boutron-Ruault; Julie E. Buring; Stephen J. Chanock; Sandra Clipp; J. Michael Gaziano; Edward Giovannucci; Susan E. Hankinson; Patricia Hartge; Robert N. Hoover; David J. Hunter; Amy Hutchinson

BACKGROUND Obesity has been proposed as a risk factor for pancreatic cancer. METHODS Pooled data were analyzed from the National Cancer Institute Pancreatic Cancer Cohort Consortium (PanScan) to study the association between prediagnostic anthropometric measures and risk of pancreatic cancer. PanScan applied a nested case-control study design and included 2170 cases and 2209 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression for cohort-specific quartiles of body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]), weight, height, waist circumference, and waist to hip ratio as well as conventional BMI categories (underweight, <18.5; normal weight, 18.5-24.9; overweight, 25.0-29.9; obese, 30.0-34.9; and severely obese, > or = 35.0). Models were adjusted for potential confounders. RESULTS In all of the participants, a positive association between increasing BMI and risk of pancreatic cancer was observed (adjusted OR for the highest vs lowest BMI quartile, 1.33; 95% CI, 1.12-1.58; P(trend) < .001). In men, the adjusted OR for pancreatic cancer for the highest vs lowest quartile of BMI was 1.33 (95% CI, 1.04-1.69; P(trend) < .03), and in women it was 1.34 (95% CI, 1.05-1.70; P(trend) = .01). Increased waist to hip ratio was associated with increased risk of pancreatic cancer in women (adjusted OR for the highest vs lowest quartile, 1.87; 95% CI, 1.31-2.69; P(trend) = .003) but less so in men. CONCLUSIONS These findings provide strong support for a positive association between BMI and pancreatic cancer risk. In addition, centralized fat distribution may increase pancreatic cancer risk, especially in women.


American Journal of Epidemiology | 2010

Circulating 25-Hydroxyvitamin D and Risk of Pancreatic Cancer Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

Rachael Z. Stolzenberg-Solomon; Eric J. Jacobs; Alan A. Arslan; Dai Qi; Alpa V. Patel; Kathy J. Helzlsouer; Stephanie J. Weinstein; Marjorie L. McCullough; Mark P. Purdue; Xiao Ou Shu; Kirk Snyder; Jarmo Virtamo; Kai Yu; Anne Zeleniuch-Jacquotte; Wei Zheng; Demetrius Albanes; Qiuyin Cai; Chinonye Harvey; Richard B. Hayes; Sandra Clipp; Ronald L. Horst; Lonn Irish; Karen Koenig; Loic Le Marchand; Laurence N. Kolonel

Results from epidemiologic studies examining pancreatic cancer risk and vitamin D intake or 25-hydroxyvitamin D (25(OH)D) concentrations (the best indicator of vitamin D derived from diet and sun) have been inconsistent. Therefore, the authors conducted a pooled nested case-control study of participants from 8 cohorts within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP) (1974–2006) to evaluate whether prediagnostic circulating 25(OH)D concentrations were associated with the development of pancreatic cancer. In total, 952 incident pancreatic adenocarcinoma cases occurred among participants (median follow-up, 6.5 years). Controls (n = 1,333) were matched to each case by cohort, age, sex, race/ethnicity, date of blood draw, and follow-up time. Conditional logistic regression analysis was used to calculate smoking-, body mass index-, and diabetes-adjusted odds ratios and 95% confidence intervals for pancreatic cancer. Clinically relevant 25(OH)D cutpoints were compared with a referent category of 50–<75 nmol/L. No significant associations were observed for participants with lower 25(OH)D status. However, a high 25(OH)D concentration (≥100 nmol/L) was associated with a statistically significant 2-fold increase in pancreatic cancer risk overall (odds ratio = 2.12, 95% confidence interval: 1.23, 3.64). Given this result, recommendations to increase vitamin D concentrations in healthy persons for the prevention of cancer should be carefully considered.


Cancer Research | 2006

A Prospective Study of Serum C-Reactive Protein and Colorectal Cancer Risk in Men

Marc J. Gunter; Rachael Z. Stolzenberg-Solomon; Amanda J. Cross; Michael F. Leitzmann; Stephanie J. Weinstein; Richard J. Wood; Jarmo Virtamo; Philip R. Taylor; Demetrius Albanes; Rashmi Sinha

Chronic inflammation has been implicated in the etiology of colorectal cancer. C-reactive protein (CRP), a sensitive marker of inflammation, has been investigated with regard to colorectal cancer in only three previous studies, and the results from these investigations were inconsistent. We examined serum CRP levels in relation to colorectal cancer incidence in a nested case-control study within the Alpha Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study, a cohort of 29,133 Finnish males enrolled from 1985 to 1988 with follow-up through April 2002. Colorectal cancer cases were ascertained by the Finnish Cancer Registry; this analysis included 130 cases of colorectal cancer (with available blood), which occurred between 1990 and April 30, 2002, and 260 matched controls. Baseline median CRP levels were approximately 25% higher among colorectal cancer cases (3.4 mg/L) than controls (2.6 mg/L; P = 0.04). Relative to men in the lowest quartile of CRP concentration, men in the highest quartile had an odds ratio of 2.9 (95% confidence interval, 1.4-6.0) for developing colorectal cancer with a dose-response relationship supported (P(trend) = 0.006). The relation between CRP and incident colorectal cancer was modified by body mass index such that the association was stronger among lean individuals than in heavier individuals (P(interaction) = 0.018). These results support the notion that chronic low-grade inflammation is a marker for increased risk of colorectal cancer.


American Journal of Epidemiology | 2009

Cigarette Smoking and Pancreatic Cancer: A Pooled Analysis From the Pancreatic Cancer Cohort Consortium

Shannon M. Lynch; Alina Vrieling; Jay H. Lubin; Peter Kraft; Julie B. Mendelsohn; Patricia Hartge; Federico Canzian; Emily Steplowski; Alan A. Arslan; Myron D. Gross; Kathy J. Helzlsouer; Eric J. Jacobs; Andrea Z. LaCroix; Gloria M. Petersen; Wei Zheng; Demetrius Albanes; Laufey Amundadottir; Sheila Bingham; Paolo Boffetta; Marie-Christine Boutron-Ruault; Stephen J. Chanock; Sandra Clipp; Robert N. Hoover; Kevin B. Jacobs; Karen C. Johnson; Charles Kooperberg; Juhua Luo; Catherine R. Messina; Domenico Palli; Alpa V. Patel

Smoking is an established risk factor for pancreatic cancer; however, detailed examination of the association of smoking intensity, smoking duration, and cumulative smoking dose with pancreatic cancer is limited. The authors analyzed pooled data from the international Pancreatic Cancer Cohort Consortium nested case-control study (1,481 cases, 1,539 controls). Odds ratios and 95% confidence intervals were calculated by using unconditional logistic regression. Smoking intensity effects were examined with an excess odds ratio model that was linear in pack-years and exponential in cigarettes smoked per day and its square. When compared with never smokers, current smokers had a significantly elevated risk (odds ratio (OR) = 1.77, 95% confidence interval (CI): 1.38, 2.26). Risk increased significantly with greater intensity (> or =30 cigarettes/day: OR = 1.75, 95% CI: 1.27, 2.42), duration (> or =50 years: OR = 2.13, 95% CI: 1.25, 3.62), and cumulative smoking dose (> or =40 pack-years: OR = 1.78, 95% CI: 1.35, 2.34). Risk more than 15 years after smoking cessation was similar to that for never smokers. Estimates of excess odds ratio per pack-year declined with increasing intensity, suggesting greater risk for total exposure delivered at lower intensity for longer duration than for higher intensity for shorter duration. This finding and the decline in risk after smoking cessation suggest that smoking has a late-stage effect on pancreatic carcinogenesis.


Cancer Research | 2006

A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers

Rachael Z. Stolzenberg-Solomon; Reinhold Vieth; Azar Azad; Pirjo Pietinen; Philip R. Taylor; Jarmo Virtamo; Demetrius Albanes

Sun exposure is associated with lower death rates for pancreatic cancer in some ecological studies. Skin exposure to UVB light induces cutaneous production of precursors to 25-hydroxyvitamin D [25(OH)D]. Pancreatic islet and duct cells express 25(OH)D(3)-1alpha-hydroxylase that generates the biologically active 1,25(OH)(2) vitamin D form. Thus, 25(OH)D concentrations could affect pancreatic function and possibly pancreatic cancer etiology. We conducted a prospective nested case-control study in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention cohort of male Finnish smokers, ages 50 to 69 years at baseline, to test whether more adequate vitamin D status, as determined by prediagnostic serum 25(OH)D concentrations, was associated with lower pancreatic cancer risk. Two hundred incident exocrine pancreatic cancer cases that occurred between 1985 and 2001 (up to 16.7 years of follow-up) were matched by age and date of blood draw to 400 controls who were alive and free of cancer at the time the case was diagnosed. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Higher vitamin D concentrations were associated with a 3-fold increased risk for pancreatic cancer (highest versus lowest quintile, >65.5 versus <32.0 nmol/L: OR, 2.92; 95% CI, 1.56-5.48, P(trend) = 0.001) that remained after excluding cases diagnosed early during follow-up. Contrary to expectations, subjects with higher prediagnostic vitamin D status had an increased pancreatic cancer risk compared with those with lower status. Our findings need to be replicated in other populations and caution is warranted in their interpretation and implication. Our results are intriguing and may provide clues that further the understanding of the etiology of this highly fatal cancer.


The Journal of Steroid Biochemistry and Molecular Biology | 2010

Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women

Kaye E. Brock; Wen-Yi Huang; David R. Fraser; Liang Ke; Marilyn Tseng; Rachael Z. Stolzenberg-Solomon; Ulrike Peters; Jiyoung Ahn; Mark P. Purdue; Rebecca S. Mason; Catherine A. McCarty; Regina G. Ziegler; Barry I. Graubard

The aim of this study was to investigate modifiable predictors of vitamin D status in healthy individuals, aged 55-74, and living across the USA. Vitamin D status [serum 25-hydroxyvitamin D (25(OH)D)] was measured along with age and season at blood collection, demographics, anthropometry, physical activity (PA), diet, and other lifestyle factors in 1357 male and 1264 female controls selected from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Multivariate linear and logistic regression analyses were used to identify associations with vitamin D status. Three%, 29% and 79% of the population had serum 25(OH)D levels<25, <50 and <80 nmol/L, respectively. The major modifiable predictors of low vitamin D status were low vitamin D dietary and supplement intake, body mass index (BMI) >30 kg/m2, physical inactivity (PA) and low milk and calcium supplement intake. In men, 25(OH)D was determined more by milk intake on cereal and in women, by vitamin D and calcium supplement and menopausal hormone therapy (MHT) use. Thus targeting an increase in vigorous activity and vitamin D and calcium intake and decreasing obesity could be public health interventions independent of sun exposure to improve vitamin D status in middle-aged Americans.


PLOS Genetics | 2011

Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption

Marilyn C. Cornelis; Keri L. Monda; Kai Yu; Nina P. Paynter; Elizabeth M. Azzato; Siiri Bennett; Sonja I. Berndt; Eric Boerwinkle; Stephen J. Chanock; Nilanjan Chatterjee; David Couper; Gary C. Curhan; Gerardo Heiss; Frank B. Hu; David J. Hunter; Kevin B. Jacobs; Majken K. Jensen; Peter Kraft; Maria Teresa Landi; Jennifer A. Nettleton; Mark P. Purdue; Preetha Rajaraman; Eric B. Rimm; Lynda M. Rose; Nathaniel Rothman; Debra T. Silverman; Rachael Z. Stolzenberg-Solomon; Amy F. Subar; Meredith Yeager; Daniel I. Chasman

We report the first genome-wide association study of habitual caffeine intake. We included 47,341 individuals of European descent based on five population-based studies within the United States. In a meta-analysis adjusted for age, sex, smoking, and eigenvectors of population variation, two loci achieved genome-wide significance: 7p21 (P = 2.4×10−19), near AHR, and 15q24 (P = 5.2×10−14), between CYP1A1 and CYP1A2. Both the AHR and CYP1A2 genes are biologically plausible candidates as CYP1A2 metabolizes caffeine and AHR regulates CYP1A2.


International Journal of Cancer | 2011

A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk

Jeanine M. Genkinger; Donna Spiegelman; Kristin E. Anderson; Leslie Bernstein; Piet A. van den Brandt; Eugenia E. Calle; Dallas R. English; Aaron R. Folsom; Jo L. Freudenheim; Charles S. Fuchs; Graham G. Giles; Edward Giovannucci; Pamela L. Horn-Ross; Susanna C. Larsson; Michael F. Leitzmann; Satu Männistö; James R. Marshall; Anthony B. Miller; Alpa V. Patel; Thomas E. Rohan; Rachael Z. Stolzenberg-Solomon; Bas A.J. Verhage; Jarmo Virtamo; Bradley J. Willcox; Alicja Wolk; Regina G. Ziegler; Stephanie A. Smith-Warner

Epidemiologic studies of pancreatic cancer risk have reported null or nonsignificant positive associations for obesity, while associations for height have been null. Waist and hip circumference have been evaluated infrequently. A pooled analysis of 14 cohort studies on 846,340 individuals was conducted; 2,135 individuals were diagnosed with pancreatic cancer during follow‐up. Study‐specific relative risks (RRs) and 95% confidence intervals (CIs) were calculated by Cox proportional hazards models, and then pooled using a random effects model. Compared to individuals with a body mass index (BMI) at baseline between 21–22.9 kg/m2, pancreatic cancer risk was 47% higher (95%CI:23–75%) among obese (BMI ≥ 30 kg/m2) individuals. A positive association was observed for BMI in early adulthood (pooled multivariate [MV]RR = 1.30, 95%CI = 1.09–1.56 comparing BMI ≥ 25 kg/m2 to a BMI between 21 and 22.9 kg/m2). Compared to individuals who were not overweight in early adulthood (BMI < 25 kg/m2) and not obese at baseline (BMI < 30 kg/m2), pancreatic cancer risk was 54% higher (95%CI = 24–93%) for those who were overweight in early adulthood and obese at baseline. We observed a 40% higher risk among individuals who had gained BMI ≥ 10 kg/m2 between BMI at baseline and younger ages compared to individuals whose BMI remained stable. Results were either similar or slightly stronger among never smokers. A positive association was observed between waist to hip ratio (WHR) and pancreatic cancer risk (pooled MVRR = 1.35 comparing the highest versus lowest quartile, 95%CI = 1.03–1.78). BMI and WHR were positively associated with pancreatic cancer risk. Maintaining normal body weight may offer a feasible approach to reducing morbidity and mortality from pancreatic cancer.

Collaboration


Dive into the Rachael Z. Stolzenberg-Solomon's collaboration.

Top Co-Authors

Avatar

Demetrius Albanes

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jarmo Virtamo

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arthur Schatzkin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Laufey Amundadottir

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Rashmi Sinha

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Wei Zheng

Vanderbilt University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge